EcoDrugPlus

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSHCOG00000000809
Gene Symbol: HTR1A
2 Cross references
104 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSHCOG00000014607
Gene Symbol: HTR1B
4 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSHCOG00000008186
Gene Symbol: HTR1F
2 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSHCOG00000003693
Gene Symbol: HTR2A
1 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSHCOG00000010933
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSHCOG00000002965
Gene Symbol: LOC109516666
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSHCOG00000010180
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSHCOG00000006309
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSHCOG00000011954
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSHCOG00000004211
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSHCOG00000014435
Gene Symbol: LOC109528618
3 Cross references
407 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSHCOG00000016089
Gene Symbol: LOC109513420
4 Cross references
325 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).